Table 2 Thematic analysis of cancer PACE meeting summaries
Themes | Frequency (n = 45) | Incorporated in CEE? | |
|---|---|---|---|
Characteristics of the disease: | 40 | ||
Poor prognosis | 30 | ~ | |
Heavily symptomatic | 24 | ~ | |
Devastating impact on patient and family | 19 | x | |
Patients are young | 12 | x | |
Psychological impact on patient | 10 | √ | |
Patient benefits of the drug: | 45 | ||
Tolerability | 31 | ~ | |
Increase in overall survival | 26 | √ | |
Improved progression-free survival | 21 | √ | |
Issues with status quo treatments | 19 | √ | |
Productivity | 18 | x | |
Value of extra time | 17 | √ | |
Normal life | 17 | ~ | |
Better symptom control | 16 | √ | |
Independence | 16 | ~ | |
Quality of life | 15 | √ | |
Reduces anxiety/gives hope | 11 | ~ | |
Trial evidence underestimates drug benefit | 10 | √ | |
Drug options and treatment pathways: | 45 | ||
Currently limited options | 30 | √ | |
Convenience | 23 | x | |
Additional treatment option | 14 | ~ | |
Innovative therapy | 13 | x | |
No recent development in this disease | 10 | x | |
General issues: | 27 | ||
(Very) strong support for this medicine | 14 | x | |
Should be made available in line with indication | 11 | x | |
Total comments | 527 | ||